Protalix Biotherapeutics vs Verastem
Protalix Biotherapeutics is the larger business, with $52.7m of revenue in fiscal 2025 against $30.9m for Verastem (1.7 times as much). Verastem grew faster (209.1% against -1.2%). Protalix Biotherapeutics kept more of each dollar of sales as profit: a net margin of -12.5% against -677.6%. Protalix Biotherapeutics carries less debt relative to equity (0.0% against 133.5%).
| Latest fiscal year | Protalix BiotherapeuticsPLX, 2025 | VerastemVSTM, 2025 |
|---|---|---|
| Revenue | $52.7m | $30.9m |
| Revenue growth | -1.2% | 209.1% |
| Net income | −$6.6m | −$209m |
| Operating margin | -10.4% | -550.3% |
| Net margin | -12.5% | -677.6% |
| Return on equity | -14.4% | — |
| Free cash flow | −$13.6m | −$138m |
| Cash | $14.7m | $205m |
| Total debt | $0 | $76.3m |
| Debt to equity | 0.0% | 133.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 226 | 102 |
| Market value | $203m | $884m |
| Price vs our value range | — | — |
| Moat score | 27 (Weak) | 28 (Weak) |
| Insider trades, 12 months | 1 buys, 1 sales | 0 buys, 33 sales |